MARKET

OCUL

OCUL

Ocular Therapeut
NASDAQ
7.99
-0.10
-1.24%
After Hours: 7.99 0 0.00% 16:41 01/22 EST
OPEN
8.09
PREV CLOSE
8.09
HIGH
8.09
LOW
7.85
VOLUME
954.86K
TURNOVER
--
52 WEEK HIGH
11.78
52 WEEK LOW
3.850
MARKET CAP
1.26B
P/E (TTM)
-6.1259
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at OCUL last week (0113-0117)?
Weekly Report · 2d ago
OCULAR THERAPEUTIX™ REPORTS INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 5d ago
Piper Sandler Keeps Their Buy Rating on Ocular Therapeutix (OCUL)
TipRanks · 6d ago
Ocular Therapeutix (OCUL) Gets a Buy from TD Cowen
TipRanks · 01/15 12:35
Ocular Therapeutix shares SOLR-R enrollment progress, next steps AXPAXLI
TipRanks · 01/14 12:15
Ocular Therapeutix Showcases Progress on AXPAXLI for Wet AMD and Diabetic Retinopathy at JPM 2025
Benzinga · 01/14 12:15
OCULAR THERAPEUTIX INC: FIRST WET AMD REGISTRATIONAL TRIAL, SOL-1, COMPLETED RANDOMIZATION IN DECEMBER 2024 WITH TOPLINE DATA ANTICIPATED IN Q4 2025
Reuters · 01/14 12:01
Ocular Therapeutix™ Shares SOL-R Enrollment Progress and Next Steps for AXPAXLI™ in NPDR
Barchart · 01/14 06:00
More
About OCUL
Ocular Therapeutix, Inc. is a biopharmaceutical company. The Company is engaged in the development and commercialization of therapies for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other diseases and conditions of the eye. Its first commercial drug product, DEXTENZA, is for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis. It is also developing two other clinical-stage assets, OTX-DED (dexamethasone intracanalicular insert) for the short-term treatment of the signs and symptoms of dry eye disease, and OTX-CSI (cyclosporine intracanalicular insert) for the chronic treatment of dry eye disease. It is conducting a pivotal Phase III clinical trial to evaluate AXPAXLI for the treatment of wet AMD. Its clinical portfolio also includes PAXTRAVA, which is in Phase III clinical development for the treatment of primary open-angle glaucoma (OAG) or ocular hypertension (OHT).

Webull offers Ocular Therapeutix Inc stock information, including NASDAQ: OCUL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OCUL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading OCUL stock methods without spending real money on the virtual paper trading platform.